5 Best-Performing S&P 500 Stocks in the Last 10 Years

In this article, we discuss 5 best performing S&P 500 stocks in the last 10 years. If you want to see more stocks in this list, click 10 Best-Performing S&P 500 Stocks in the Last 10 Years. 

5. DexCom, Inc. (NASDAQ:DXCM)

Number of Hedge Fund Holders: 56

10-Year Share Price Returns as of September 13: 2,450%

DexCom, Inc. (NASDAQ:DXCM) was incorporated in 1999 and is headquartered in San Diego, California. It is a medical device company, focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The stock has gained 2,450% in the last decade as of September 13, and DexCom, Inc. (NASDAQ:DXCM) is one of the best performing S&P 500 constituents. 

On July 29, Oppenheimer analyst Steven Lichtman maintained an Outperform rating on DexCom, Inc. (NASDAQ:DXCM) but lowered the price target on the shares to $105 from $131. The analyst believes the post-earnings selloff is a buying opportunity.

According to Insider Monkey’s Q2 data, 56 hedge funds were bullish on DexCom, Inc. (NASDAQ:DXCM), compared to 58 funds in the last quarter. Ken Griffin’s Citadel Investment Group is the leading position holder in the company, with more than 3 million shares worth about $229 million. 

Here is what Baron Small Cap Fund has to say about DexCom, Inc. (NASDAQ:DXCM) in its Q2 2022 investor letter:

“DexCom, Inc. is the leading provider of continuous glucose monitoring systems for patients with diabetes. The stock fell along with other premium valuation growth stocks, primarily on multiple contraction. Concern about price competition from Abbott Labs’ Libre product also played a role. Results for the first quarter were solid. Sales increased 22% organically, margins expanded 350 basis points, and the company maintained guidance for continued strong results.

An important new and revolutionary product, the G7, was approved and launched in Europe, and the company expects it to be approved in the U.S. soon. The product is 60% smaller, fully disposable, and designed for extended wear. We remain excited that CGM will become the standard of care for Type 1 diabetics and will be used extensively for Type 2 diabetics as well, which we think will be a major driver of continued sales and profit growth well into the future.”